The phase II study for evaluating the effectiveness and safety of allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia with FLT3/ITD mutation. -JALSG AML209-FLT3-SCT Study (AML209-FLT3-SCT)
- Conditions
- Acute myeloid leukemia
- Registration Number
- JPRN-UMIN000003433
- Lead Sponsor
- Japan adult leukemia study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 60
Not provided
(1)Secondary AML (2)The patients with the past history of hematopoietic disorder. (3)The patients who received the induction therapy consisted of Gemtuzumab ozogamicin (Mylotarg). (4)The patients who have been identified the cancer after the registration to the JALSG AML209-GS study. (5)The patients who have developed myocardial infarction or angina after the registration to the JALSG AML209-GS study. (6)The patients with cardiac dysfunction. (7)The patients with active gastric ulcer. (8)The patients with the uncontrollable ileus. (9)The patients with the diabetes mellitus. (10)The patients with active infection. (11)The patients in whom the HBV-reactivation have been observed. (12)Psycological patients.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease-free survival at the 3 year.
- Secondary Outcome Measures
Name Time Method